Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated:  5/30/2014
Washington University
397
mi
from 43215
St. Louis, MO
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated: 5/30/2014
Washington University
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated:  5/30/2014
Cincinnati Children's Hospital in partnership with University Hospital of Cincinnati
95
mi
from 43215
Cincinnati, OH
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated: 5/30/2014
Cincinnati Children's Hospital in partnership with University Hospital of Cincinnati
95
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated:  5/30/2014
University of Virginia
275
mi
from 43215
Charlottesville, VA
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated: 5/30/2014
University of Virginia
275
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Randomized, Crossover Safety and Pharmacokinetics Study of PT010
A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days
Status: Enrolling
Updated:  7/22/2014
SNBL Clinical Pharmacology Center
343
mi
from 43215
Baltimore, MD
Randomized, Crossover Safety and Pharmacokinetics Study of PT010
A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days
Status: Enrolling
Updated: 7/22/2014
SNBL Clinical Pharmacology Center
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Advanced Pharma CR, LLC
994
mi
from 43215
Miami, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Advanced Pharma CR, LLC
994
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Elite Research Institute
983
mi
from 43215
Miami, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Elite Research Institute
983
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Compass Research LLC
795
mi
from 43215
Orlando, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Compass Research LLC
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
University at Buffalo CTRC
294
mi
from 43215
Buffalo, NY
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
University at Buffalo CTRC
294
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Volunteer Research Group
283
mi
from 43215
Knoxville, TN
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Volunteer Research Group
283
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
1980
mi
from 43215
Torrance, CA
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
1980
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
531
mi
from 43215
Waterbury, CT
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
531
mi
from 43215
Waterbury, CT
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
561
mi
from 43215
Savannah, GA
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
561
mi
from 43215
Savannah, GA
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
316
mi
from 43215
Normal, IL
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
316
mi
from 43215
Normal, IL
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
1614
mi
from 43215
Missoula, MT
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
1614
mi
from 43215
Missoula, MT
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
95
mi
from 43215
Cincinnati, OH
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
95
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
3
mi
from 43215
Columbus, OH
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
3
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
351
mi
from 43215
Spartanburg, SC
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
351
mi
from 43215
Spartanburg, SC
Click here to add this to my saved trials
Efficacy and Safety of AQX-1125 in Unstable COPD
The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway
Status: Enrolling
Updated:  10/23/2014
University of Cincinnati
98
mi
from 43215
Cincinnati, OH
Efficacy and Safety of AQX-1125 in Unstable COPD
The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway
Status: Enrolling
Updated: 10/23/2014
University of Cincinnati
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated:  10/31/2014
Dayton VA Medical Center
63
mi
from 43215
Dayton, OH
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated: 10/31/2014
Dayton VA Medical Center
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated:  10/31/2014
Dayton VA Medical Center
63
mi
from 43215
Dayton, OH
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated: 10/31/2014
Dayton VA Medical Center
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Status: Enrolling
Updated:  12/8/2014
Moses Taylor Hospital
398
mi
from 43215
Scranton, PA
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Status: Enrolling
Updated: 12/8/2014
Moses Taylor Hospital
398
mi
from 43215
Scranton, PA
Click here to add this to my saved trials
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Status: Enrolling
Updated:  1/13/2015
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
477
mi
from 43215
New York, NY
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Status: Enrolling
Updated: 1/13/2015
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
Status: Enrolling
Updated:  1/15/2015
GSK Investigational Site
343
mi
from 43215
Baltimore, MD
To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
Status: Enrolling
Updated: 1/15/2015
GSK Investigational Site
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Respiratory Disease Management
Use of a Respiratory Care Practitioner Disease Management (RCP-DM) Program for Patients Hospitalized With COPD
Status: Enrolling
Updated:  1/26/2015
Barnes Jewish Hospital
397
mi
from 43215
St. Louis, MO
Respiratory Disease Management
Use of a Respiratory Care Practitioner Disease Management (RCP-DM) Program for Patients Hospitalized With COPD
Status: Enrolling
Updated: 1/26/2015
Barnes Jewish Hospital
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Status: Enrolling
Updated:  4/3/2015
EPI-Q
288
mi
from 43215
Oak Brook, IL
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Status: Enrolling
Updated: 4/3/2015
EPI-Q
288
mi
from 43215
Oak Brook, IL
Click here to add this to my saved trials
A Registry of COPD Patients to be Used for Future Studies
The Ohio State University COPD Registry
Status: Enrolling
Updated:  4/20/2015
Ohio State University
2
mi
from 43215
Columbus, OH
A Registry of COPD Patients to be Used for Future Studies
The Ohio State University COPD Registry
Status: Enrolling
Updated: 4/20/2015
Ohio State University
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Status: Enrolling
Updated:  5/18/2015
Baylor College of Medicine
991
mi
from 43215
Houston, TX
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Status: Enrolling
Updated: 5/18/2015
Baylor College of Medicine
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device
Monitoring COPD Patients at Home by a Forced Oscillation Technique Device
Status: Enrolling
Updated:  6/2/2015
Baylor College of Medicine
mi
from 43215
Houston, Texas, TX
Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device
Monitoring COPD Patients at Home by a Forced Oscillation Technique Device
Status: Enrolling
Updated: 6/2/2015
Baylor College of Medicine
mi
from 43215
Houston, Texas, TX
Click here to add this to my saved trials
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Status: Enrolling
Updated:  7/2/2015
Columbia University Cardiopulmonary, Sleep and Ventilatory Disorders Center
481
mi
from 43215
NY, NY
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Status: Enrolling
Updated: 7/2/2015
Columbia University Cardiopulmonary, Sleep and Ventilatory Disorders Center
481
mi
from 43215
NY, NY
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
628
mi
from 43215
Andalusia, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
628
mi
from 43215
Andalusia, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
462
mi
from 43215
Anniston, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
462
mi
from 43215
Anniston, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
417
mi
from 43215
Athens, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
417
mi
from 43215
Athens, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
491
mi
from 43215
Birmingham, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
491
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1650
mi
from 43215
Mesa, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1650
mi
from 43215
Mesa, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1662
mi
from 43215
Phoenix, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1662
mi
from 43215
Phoenix, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1653
mi
from 43215
Scottsdale, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1653
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1639
mi
from 43215
Tucson, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1960
mi
from 43215
Anaheim, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1960
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1949
mi
from 43215
Carlsbad, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1949
mi
from 43215
Carlsbad, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1971
mi
from 43215
Lakewood, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1971
mi
from 43215
Lakewood, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1972
mi
from 43215
Los Angeles, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1964
mi
from 43215
Pasadena, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1964
mi
from 43215
Pasadena, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1969
mi
from 43215
Pasedena, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1969
mi
from 43215
Pasedena, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1938
mi
from 43215
Poway, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1938
mi
from 43215
Poway, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
2043
mi
from 43215
Sacramento, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
2043
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1951
mi
from 43215
San Diego, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1958
mi
from 43215
Tustin, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1958
mi
from 43215
Tustin, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1969
mi
from 43215
Vista, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1969
mi
from 43215
Vista, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
1969
mi
from 43215
Vista, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
1969
mi
from 43215
Vista, CA
Click here to add this to my saved trials